In the absence or combination treatment or agent to further radiation therapy or other anti-cancer drugs, the present invention provides an irinotecan and human IgG1 antibody anti-EGFR for use in combination to the combination treatment of cancer. The invention further encompasses a pharmaceutical composition comprising, in a carrier which may be pharmaceutically acceptable, a combination of irinotecan and human IgG1 antibody anti-EGFR. [Selection] Figure Figure 1本発明は、他の抗癌薬や放射線療法等の更なる剤や処置の併用又は不在下で、癌の併用処置に併用するためのヒト化抗EGFR IgG1抗体及びイリノテカンを提供する。本発明は更に、ヒト化抗EGFR IgG1抗体及びイリノテカンの組み合わせを、医薬的に許容され得る担体中に含んでなる医薬組成物を包含する。【選択図】図1
